Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.16) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($1.35) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($0.95) EPS.

Separately, Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Fulcrum Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.63.

Fulcrum Therapeutics Trading Up 6.5 %

NASDAQ FULC opened at $3.59 on Wednesday. The company has a fifty day simple moving average of $4.11 and a 200 day simple moving average of $4.57. The company has a market cap of $193.64 million, a P/E ratio of -11.58 and a beta of 2.03. Fulcrum Therapeutics has a 1 year low of $2.86 and a 1 year high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Equities research analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after buying an additional 2,155,675 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Fulcrum Therapeutics by 50.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock valued at $14,100,000 after buying an additional 1,000,000 shares in the last quarter. State Street Corp raised its stake in shares of Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after buying an additional 638,955 shares in the last quarter. Woodline Partners LP raised its stake in shares of Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after buying an additional 739,713 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after buying an additional 13,485 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.